* Q4 loss/shr $0.19 vs est loss/shr $0.22
* Q4 rev $4.2 mln vs est $4.3 mln
March 3 Pharmaceutical company Pozen Inc
POZN.O, which focuses on developing pain drugs, posted a
narrower-then-expected quarterly loss, helped by a 42 percent
drop in operating expenses.
For the fourth quarter, the company posted a net loss of
$5.8 million, or 19 cents a share, compared with a net loss of
$4.1 million, or 14 cents a share, in the year-ago period.
Revenue for the quarter was $4.2 million.
Analysts on average had expected a loss of 22 cents, on
revenue of $4.3 million, according to Thomson Reuters I/B/E/S.
Operating expenses fell to $10.7 million from $18.5
million, primarily due to a decrease in costs associated with
the development program for its pain drug Vimovo.
The company said it expects to hear from U.S. health
regulators regarding the marketing application for Vimovo in
the second quarter.
Shares of Pozen closed at $6.38 Tuesday on Nasdaq.
For the alerts, please click on [ID:nWNAB4582]
(Reporting by Jennifer Robin Raj in Bangalore; Editing by